Markets:

News

Articles published by Aro Biotherapeutics

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Today 8:30 EDT

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

February 05, 2026

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium

January 20, 2026

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)

September 24, 2025

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

February 11, 2025

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD)

February 05, 2025

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)

January 23, 2025

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer

January 07, 2025

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)

October 29, 2024

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting

February 06, 2024

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Secures $41.5M Series B Financing

November 28, 2023

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease

October 25, 2023

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease

September 15, 2022

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease

August 10, 2022

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease

May 11, 2022

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences

March 30, 2022

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Expands Leadership Team with Appointment of Sukumar Sakamuri, Ph.D. as Chief Technology Officer

January 12, 2022

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Appoints Mittie Doyle, MD, FACR as Chief Medical Officer

October 07, 2021

From Aro Biotherapeutics

Via Business Wire

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

August 04, 2021

From Aro Biotherapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.